Who Paid My Doc
Scott Justesen
Orthopaedic Trauma Price, UT Medical Doctor
NPI 1821044595 CMS profile 1013161
945 W Hospital Dr Ste 7, Price, UT 84501
General payments
$3,383
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Scott Justesen of Price, UT is reported in the CMS Open Payments database as having received $3,383 across 37 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $471 | 11 | |
| 2024 | General | $18 | 1 | |
| 2023 | General | $61 | 4 | |
| 2022 | General | $2,494 | 13 | |
| 2021 | General | $31 | 1 | |
| 2020 | General | $29 | 2 | |
| 2019 | General | $280 | 5 |
Beside peers
- Scott Justesen
- Orthopaedic Trauma median
- Middle half of Orthopaedic Trauma
- National median
In program year 2025, general payments to Scott Justesen were reported at $471. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.
Show as a table
| Year | Scott Justesen | Orthopaedic Trauma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $280 | $1,475 | $264–$6,401 | $163 |
| 2020 | $29 | $596 | $120–$4,020 | $114 |
| 2021 | $31 | $919 | $171–$4,697 | $132 |
| 2022 | $2,494 | $1,547 | $272–$7,240 | $149 |
| 2023 | $61 | $1,330 | $247–$5,875 | $160 |
| 2024 | $18 | $1,288 | $277–$6,797 | $164 |
| 2025 | $471 | $1,227 | $259–$7,433 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
397
Drug cost
$8,439
Branded share of claims
49.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 20 | $5,863 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 88 | $919 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 76 | $901 | |
| Tramadol Hcl | Generic | 99 | $380 | |
| Ibuprofen | Generic | 24 | $176 | |
| Cyclobenzaprine Hcl | Generic | 11 | $57 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 13 | $40 | |
| Prednisone | Generic | 28 | $40 | |
| Meloxicam | Generic | 13 | $38 | |
| Amoxicillin | Generic | 25 | $24 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 85 billing codesPaid by Medicare
$194,013
Medicare patients
415
Services billed
3,175
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 69% | |
| Depression | 33% | |
| Diabetes | 29% | |
| Ischemic heart disease | 21% | |
| Heart failure | 19% | |
| Chronic kidney disease | 19% | |
| COPD | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 | Office | 14 | 80 | $7,871 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 81 | 193 | $768 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 161 | 534 | $408 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 21 | 45 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
37 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Trauma in Utah
Related records
Orthopaedic Trauma in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Trauma
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.